Journal
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume 46, Issue 3, Pages 658-668Publisher
WILEY-HINDAWI
DOI: 10.1111/jcpt.13318
Keywords
chronic kidney disease; cost‐ effectiveness; non‐ valvular atrial fibrillation; rivaroxaban; warfarin
Categories
Funding
- Zhejiang Medical and Health Science and Technology Project [2018RC031]
Ask authors/readers for more resources
The study found that rivaroxaban therapy was cost-effective compared to warfarin for NVAF patients with different renal function levels. Results were consistent across subgroups and remained true even under the assumption of anticoagulant discontinuation after major bleeding events.
What is known and objective In non-valvular atrial fibrillation (NVAF) patients with chronic kidney disease (CKD), rivaroxaban was not inferior to warfarin in preventing stroke and systemic embolism. However, a comparative evaluation of the cost-effectiveness of rivaroxaban and warfarin therapies for NVAF patients at different renal function levels has not yet been reported, and this study aimed to estimate the cost-effectiveness of rivaroxaban compared with warfarin in Chinese NVAF patients with CKD. Methods A Markov model was constructed to estimate quality-adjusted life years (QALYs) and lifetime costs associated with the use of rivaroxaban relative to warfarin in patients with NVAF at different estimated glomerular filtration rate (eGFR) levels as follows: 30 to <50, 50 to The incrementalQALYs with rivaroxaban was slightly increased by approximately 0.3 QALY as compared with that with warfarin in all the subgroups, resulting in an ICER of $9,736/QALY (eGFR, 30 to <50 mL/min), $9,758/QALY (50 to <80 mL/min) and $9,969/QALY (>= 80 mL/min). The probabilistic sensitivity analysis suggested a chance of >80% that the ICER would be lower than the willingness-to-pay threshold of three times the GDP of China in 2019 in all the subgroups. Results were consistent even under the assumption of anticoagulant discontinuation after major bleeding events. The model was most sensitive to event-free-related utility and survival rates. What is new and conclusion The existing evidence supports the cost-effectiveness of rivaroxaban therapy as an alternative anticoagulant to warfarin for patients with NVAF at different renal function levels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available